Popular terms

Dimethyl topics
Physiologic
Hydrochloric Acid
Fresnel Zone
Aberration
Ophthalmic
Liquid Crystal
Imaging System
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Chloric Acid
Tartaric Acid
Fumaric Acid
Antagonist
Bradykinin
Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dimethyl patents



      

This page is updated frequently with new Dimethyl-related patent applications.




Date/App# patent app List of recent Dimethyl-related patents
04/07/16
20160097349 
 Mixed fuel supply system for internal combustion engine, vehicle, and mixed fuel supply  internal combustion engine patent thumbnailMixed fuel supply system for internal combustion engine, vehicle, and mixed fuel supply internal combustion engine
A mixed fuel supply system includes a dimethyl ether (“dme”) tank which stores dme, a dme supply path which supplies the dme and a light oil supply system. The dme supply path is connected to a transfer path between a feed pump and a fuel injection pump.
Isuzu Motors Limited


04/07/16
20160097015 
 Bearing material patent thumbnailBearing material
A plastic bearing material of a bearing may include a block copolymer. The block copolymer may include structural blocks of two or more different polymers.

04/07/16
20160096863 
 Methods of preparing intermediate of fluticasone propionate patent thumbnailMethods of preparing intermediate of fluticasone propionate
A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth metal hydroxide, or a mixture thereof to cleave an amide from the 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound; treating the solution to separate an aqueous portion; and adding an acid to the aqueous portion to obtain the thioic acid intermediate of fluticasone propionate. A method of preparing fluticasone propionate includes preparing the thioic acid intermediate of fluticasone propionate, and alkylating the thioic acid intermediate of fluticasone propionate to prepare the fluticasone propionate..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096838 
 Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders patent thumbnailCrystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
Crystalline form, form t2h1.5-4, of n,ndicyclopropyl-4-(1,5-dimethyl-1 hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (compound (i)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising form t2h1.5-4 of compound (i) as well as a method of using the form t2h1.5-4 of compound (i) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


04/07/16
20160096816 
 Method of preparing intermediate of salmeterol patent thumbnailMethod of preparing intermediate of salmeterol
A method of preparing an intermediate of salmeterol (compound 1, 2-amino-1-(2,2-dimethyl-4h-1,3-benzodioxin-6-yl)ethanol) includes: reacting compound 2 with 2-methoxypropene in a first organic solvent to produce a reaction solution including compound 3, compound 2 including a 2-bromo precursor of compound 1; reacting compound 3 with a nitrogen source to produce compound 4; reacting compound 4 with sodium borohydride in a second organic solvent to produce compound 5; and debenzylating compound 5 by ammonium formate/palladium-carbon catalytic transfer hydrogenation in a third organic solvent to produce compound 1. A method of preparing salmeterol includes preparing compound 1, and reacting compound 1 to prepare salmeterol..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096807 
 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator patent thumbnailCo-crystals of modulators of cystic fibrosis transmembrane conductance regulator
The present disclosure relates to co-crystals comprising n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits..
Vertex Pharmaceuticals Incorporated


04/07/16
20160095890 
 Composition for the treatment of joint conditions patent thumbnailComposition for the treatment of joint conditions
The present invention relates to a composition for improving the health status of various joints in the human body. The composition includes at least one plant extract as fatty base with active role, at least one extract from plants with anti-microbial properties, at least one extract from plants with analgesic and/or anti-inflammatory properties, and at least one extract from plants with anti-rheumatic and regenerative properties, to which dimethylsulfoxide, allantoin and/or potassium alum may be added.

04/07/16
20160095859 
 Combination therapies for overcoming resistance to mitotic agents during chemotherapy patent thumbnailCombination therapies for overcoming resistance to mitotic agents during chemotherapy
This disclosure relates to the uses of compounds that target an interaction between chfr and parp1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits chfr and parp1 interactions, such as 5-((1-benzyl-1h-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1h,3h,5h)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent..
Emory University


03/31/16
20160090435 
 Block copolymer,  forming the same, and  forming pattern patent thumbnailBlock copolymer, forming the same, and forming pattern
Wherein com1 and com2 are independently selected from a polystyrene moiety, polymethylmethacrylate moiety, polyethylene oxide moiety, polyvinylpyridine moiety, polydimethylsiloxane moiety, polyferrocenyldimethylsilane moiety, and polyisoprene moiety, r1 is hydrogen or an alkyl group with 1 to 10 carbon atoms, ph is a phenyl group, a is 1 to 50, r2 is hydrogen or an alkyl group with 1 to 10 carbon atoms, and b is 1 to 50.. .

03/31/16
20160090385 
 Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders patent thumbnailCrystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
Crystalline form, form t1h1.5-4, of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (compound (i)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising form t1h1.5-4 of compound (i) as well as a method of using the form t1h1.5-4 of compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


03/31/16
20160090359 

Crystalline forms of an nk-1 antagonist


The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an nk-1 antagonist useful in the treatment of induced vomiting and other disorders.. .
Helsinn Healthcare Sa


03/31/16
20160090354 

Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto


A novel solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “atr-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. Atr-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (acc), congenital adrenal hyperplasia (cah) and cushing's syndrome..
Atterocor, Inc.


03/31/16
20160090308 

A process for making molecular sieves


The invention relates to a process for preparing molecular sieves, such as zsm-57, using one or more structure directing agents selected from the group consisting of n1,n1,n5,n5-tetraethyl-n1,n5-dimethylpentane-1,5-diamininum, 1-ethyl-1-(5-(1-methylpiperidin-1-ium-1-yl)pentyl)piperidin-1-ium, 1,1′-(hexane-1,6-diyl)bis(1-ethylpiperidin-1-ium), and 1,1-diethylpyrrolidin-1-ium.. .
Exxonmobil Chemical Patents Inc.


03/31/16
20160089434 

Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and/or a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and an anti-pd-l1 antibody; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or neutralizing or inhibiting the interaction between pd-l1 and its receptor, e.g. Pd-1, is beneficial, eg.
Novartis Ag


03/31/16
20160089387 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/31/16
20160089386 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/24/16
20160087066 

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide


Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido)hafnium to deposit hafnium silicate on surfaces heated to 300° c.
President And Fellows Of Harvard College


03/24/16
20160083598 

White ink


An ink comprising: (a) from 1 to 25 parts of surface treated titanium dioxide; (b) from 8 to 25 parts of a first solvent selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol and dipropylene glycol; (c) from 2 to 12 parts of a second solvent selected from the group consisting of 2-pyrrolidone, n-methyl-2-pyrrolidone, n-ethyl-2-pyrrolidone, n-cyclohexyl-2-pyrrolidone and n,n-dimethylacetamide; (d) from 15 to 45 parts of glycerol; (e) from 0.1 to 2 parts of an acetylenic surfactant; (f) from 0.001 to 2 parts of 1,2-benzisothiazolin-3-one; (g) from 0 to 20 parts of polymer particles; and (h) the balance to 100 parts water.. .
Fujifilm Imaging Colorants, Inc.


03/24/16
20160083384 

Salts and crystalline forms of an apoptosis-inducing agent


Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic bcl-2 family proteins, for example cancer.. .
Abbvie Inc.


03/24/16
20160083373 

Method for preparing afatinib and intermediate thereof


Revealed in the present invention is a method for preparing afatinib (i): using 2-nitrile-4-[4-(n,n-dimethylamino)-i-oxo-2-buten-i-yl]amino-5-[(s)-(tetrahydrofuran-3-yl)oxy]aniline (ii) and 4-fluoro-3-chloroaniline (iii) as starting materials, and respectively performing a condensation and cyclization reaction with n,n-dimethylformamide dimethyl acetal (iv) to prepare afatinib (i), wherein the method significantly reduces the manufacturing steps of afatinib and greatly lower the costs. In addition, also provided in the present invention is a method for preparing an intermediate of afatinib, wherein the method has a stable process, uses readily available starting materials, has a low cost, and all the reactions are classic reactions, suitable for meeting amplification requirements in the industry..
Suzhou Miracpharma Technology Co., Ltd.


03/24/16
20160083359 

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment


1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on sert, 5-ht3 and 5-ht1a and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.. .
H. Lundbeck A/s


03/24/16
20160083340 

Method of purifying dimethyl sulfoxide


A method of purifying dimethyl sulfoxide economically and at good yield satisfies the specifications of the united states pharmacopoeia and reduces odor. The method includes distilling a solution having 35 parts by weight or more of water admixed per 100 parts by weight of raw dimethyl sulfoxide..
Toray Fine Chemicals Co., Ltd.


03/17/16
20160077066 

Analytical detecting fuel markers


A gas chromatographic method for detecting a marker compound in a fuel by (a) introducing a sample of fuel into a first capillary column coated with a stationary phase based on polydimethylsiloxane and allowing the sample to flow through the first column to produce a first effluent; (b) allowing the first effluent to pass through a detector and identifying a retention time range in it which includes a retention time of the marker compound; (c) introducing only a portion of the first effluent stream which is within the retention time range into a second capillary column coated with either (i) an ionic sorbent or (ii) a polyethylene glycol, and allowing said portion to flow through the second capillary column to produce a second effluent stream; and (d) allowing the second effluent to pass through a detector; wherein the marker compound has formula ar(r2)m(or1)n and is present in the fuel at a level from 0.01 ppm to 100 ppm.. .
Dow Global Technologies Llc


03/17/16
20160075632 

Process of production of dehydrolinalyl acetate (i)


The present invention is related to a novel and improved process for the production of dehydrolinalyl acetate (dla), which iupac name is acetic acid 1-ethynyl-1,5-dimethyl-hex-4-enyl ester, starting from dehydrolinalool (dll), which iupac name is 3,7-dimethyloct-6-en-1-yn-3-ol, by catalytic acetylation.. .
Dsm Ip Assets B. V.


03/10/16
20160068674 

Imprint material


There is provided an imprint material that has sufficient adhesion to film substrates and excellent scratch resistance, and can be readily released from a mold at the time of mold release. An imprint material including: (a) a specific acrylamide such as n,n′-dimethylacrylamide; (b) a compound having alkylene oxide units and having 2 to 6 polymerizable groups at the ends of the compound, in which the alkylene oxide units are ethylene oxide units, propylene oxide units, or a combination thereof; and (c) a photopolymerization initiator..
Nissan Chemical Industries, Ltd.


03/10/16
20160068511 

Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof


The present invention relates to maleate salt forms of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family..
Wyeth Llc


03/10/16
20160068403 

Method for preparing zeolite ssz-52 using computationally predicted structure directing agents


A method is disclosed for preparing zeolite ssz-52 using a computationally predicted organic structure directing agent. The computationally predicted structure organic directing agent is an organic structure directing agent other than an n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation, and the difference in stabilization energy between the organic structure directing agent other than an n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation and the n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation is no more than 2.5 kj mol−1 si..
Chevron U.s.a. Inc


03/10/16
20160067956 

Release agent composition for improved coefficient of friction


A functional amine release agent displaying reduced coefficient of friction as compared to standard silicone oils, comprises a polydimethylsiloxane oil and a functional amine selected from the group consisting of pendant propylamines and pendant n-(2-aminoethyl)-3-aminopropyl. The concentration of functional amine to polydimethylsiloxane oil is approximately less than 0.0001 meq/g.
Xerox Corporation


03/10/16
20160067266 

Stabilized composition for treating psoriasis


A storage stable ointment of the present invention comprises a vitamin d compound, a corticosteroid, and an n,n-di(c1-c8) alkylamino substituted, (c4-c18) alkyl (c2-c18) carboxylic ester a (c1-c4)-alkyl (c8-c22) carboxylic ester in a petrolatum ointment base, and optionally containing mineral oil and/or tocopherol. Preferably, the vitamin d compound is calcipotriene, the corticosteroid is selected from the group consisting of clobetasol propionate and betamethasone dipropionate, and the n,n-di(c1-c8) alkylamino substituted, (c4-c18) alkyl (c2-c18) carboxylic ester comprises dodecyl 2-(n,n-dimethylamino)-propionate (ddaip)..
Nexmed Holdings, Inc.


03/10/16
20160067248 

Combinations


The present invention relates to a method of treating ovarian cancer in a female human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a ovarian cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 2-[(5-chloro-2-[[3-methyl-1-(1-methylethyl)-1h-pyrazol-5-yl]amino]-4-pyridinyl)amino]-n-methoxybenzamide, or a pharmaceutically acceptable salt thereof, and optionally 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}, to a human in need thereof..
Board Of Regents, The University Of Texas System


03/10/16
20160067206 

Composition for preventing or treating renal fibrosis comprising dimethylfumarate as active ingredient


The present invention relates to a composition for preventing or treating renal fibrosis comprising dimethylfumarate (dmf) as an active ingredient. The dmf according to the present invention has an excellent effect of reducing renal fibrosis by activating nrf2 to inhibit tgf-β/smad signaling, and thus is useful for preventing or treating renal fibrosis..
Kyungpook National University Hospital


03/03/16
20160060763 

Chemical vapor deposition process and coated article


A chemical vapor deposition process and coated article are disclosed. The chemical vapor deposition process includes positioning an article in a chemical vapor deposition chamber, then introducing a deposition gas to the chemical vapor deposition chamber at a sub-decomposition temperature that is below the thermal decomposition temperature of the deposition gas, and then heating the chamber to a super-decomposition temperature that is equal to or above the thermal decomposition temperature of the deposition gas resulting in a deposited coating on at least a surface of the article from the introducing of the deposition gas.
Silcotek Corp.


03/03/16
20160060391 

Copolymer based on dimethyl carbonate and preparing the same


A copolymer based on dimethyl carbonate and a method of preparing the same are provided. The copolymer based on dimethyl carbonate has a unit from dimethyl carbonate, diols, and a modification monomer.
National Cheng Kung University


03/03/16
20160060375 

Tulipalin a-based hydroxyl-functionalized polymers, and engineered materials prepared therefrom


A tulipalin a-based hydroxyl-functionalized (hf) polymer is synthesized by converting, via a ring opening reaction, poly(tulipalin a) or poly(tulipalin a-co-acrylic) in the presence of a nucleophilic monomer and a catalyst. The nucleophilic monomer may be, for example, a nitrogen-containing monomer such as dimethylamine.
International Business Machines Corporation


03/03/16
20160060215 

New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine


The present invention provides new intermediate compounds or formulae (iii) and (iva), and salts thereof, and their use in a new synthetic process for the production of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine) an experimental drug under development for the treatment of depression and anxiety.. .
Lek Pharmaceuticals D.d.


02/25/16
20160053224 

Methods of cell separation


The present invention relates to the use of a combination of: (i)a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (dmso), dimethylglycine (dmg) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).. .
Cells 4 Life Group Llp


02/25/16
20160052960 

Process for the preparation of drospirenone


A process is disclosed wherein, using either 17a-(3-hydroxypropyl)-6p,7p;15p,16p-dimethylene-5p-androstane-3p,5,17p-triol (ii) or 3β,5̂iîκ̂-6β,7β;15β,16β-dimethylene-5β,17α-pregnane-21,17-carbolactone (iii) as starting material, through a single-step reaction it is obtained drospirenone (i), a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action.. .
Industtiale Chimica S.r.l.


02/25/16
20160052857 

Carbonylation process


A process for the production of methyl acetate by carbonylating dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein the process is carried out with a molar ratio of hydrogen to carbon monoxide of at least 1 and the catalyst has been calcined at a temperature of from about 375° c. To about 475° c..
Bp Chemicals Limited


02/25/16
20160051608 

Anti-cancer extract and compounds


The present invention relates to a new approach for treating a cancer or fibrosis, such as hepatocellular carcinoma, or liver fibrosis using an extract from a plant of graptopetalum sp., rhodiola sp., or echeveria sp., and prepared by extracting the plant with dimethyl sulfoxide (dmso), its fraction or the compound isolated from the extract.. .
National Yang-ming University


02/18/16
20160049693 

Electrolytes for rechargeable batteries


Provided are novel electrolytes for use in rechargeable lithium ion cells containing high capacity active materials, such as silicon, germanium, tin, and/or aluminum. These novel electrolytes include one or more pyrocarbonates and, in certain embodiments, one or more fluorinated carbonates.
Amprius, Inc.


02/18/16
20160049663 

Ionomer solution containing anion-exchange resin dissolved in solvent


Provided is an ionomer solution including an anion-exchange resin and a solvent. The anion-exchange resin is dissolved in the solvent, the anion-exchange resin includes a matrix resin and an anion-exchange group, the matrix resin includes a styrene elastomer, and the anion-exchange group is a quaternary ammonium salt group having at least one unit derived from an amine selected from the group consisting of an n,n-dimethylalkylamine having an alkyl group having two or more carbon atoms and a bicycloalkane having a nitrogen atom at a bridgehead position..
Nitto Denko Corporation


02/18/16
20160049261 

Supercapacitor


Embodiments provide a hybrid supercapacitor exhibiting high energy and power densities enabled by a high-performance lithium-alloy anode coupled with a porous carbon cathode in an electrolyte containing lithium salt. Embodiments include a size reduced silicon oxide anode, a boron-doped silicon oxide anode, and/or a carbon coated silicon oxide anode, which may improve cycling stability and rate performance.
The Penn State Research Foundation


02/18/16
20160046789 

Basic stabilisation systems for emulsion polymerised rubber


There are described compositions comprising a) an emulsion crude rubber, synthetic latex or natural rubber latex subject to oxidative, thermal, dynamic and/or light-induced degradation, b) a compound of the formula (i) wherein r1 is c8-c12alkyl, r2 is hydrogen, c1-c12alkyl, cyclohexyl, 1-methylcyclohexyl, benzyl, α-methylbenzyl, α,α-dimethylbenzyl or —ch2—s—r1, r3 is c1-c12alkyl, benzyl, α-methylbenzyl, α,α-dimethylbenzyl or —ch2—s—r1, r4 is hydrogen or methyl, and c) a styrenated diphenylamine of the formula (ii).. .
Basf Se


02/18/16
20160046743 

Production vinyl ether polymer


The production method for a vinyl ether polymer of the present technology comprises the step of subjecting a vinyl ether monomer to radical polymerization in a mixed solvent to form a vinyl ether polymer. The mixed solvent is a mixed solvent in which the mass ratio of isopropyl alcohol to dimethylformamide is from 93:7 to 75:25, or a mixed solvent in which the mass ratio of isopropyl alcohol to water is from 50:50 to 5:95, and a mass ratio of the vinyl ether monomer to the mixed solvent is from 3:100 to 45:100..
The Yokohama Rubber Co., Ltd.


02/18/16
20160046663 

Controlled cross-linking processing of proteins


A method of forming a cross-linked protein structures includes preparing a solution of protein dissolved in a benign solvent and forming an intermediate protein structure from the solution. The intermediate protein structure can be cross-linked by providing for a specific ratio of chemical cross-linking agents to form the cross-linked protein structure.
Case Western Reserve University


02/18/16
20160046623 

Salt of pyrazoloquinoline derivative, and crystal thereof


The present invention provides a salt of (s)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1h-pyrazolo[4,3-c]quinolin-4(5h)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals.. .
Eisai R&d Management Co., Ltd.


02/18/16
20160045459 

Pharmaceutical combination


A combination comprising as components (a) the compound 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (nsaids); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. Chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


02/18/16
20160045458 

Pharmaceutical combination


A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. Neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


02/18/16
20160045425 

Hair care shampoo


A cleaning cosmetic composition includes, in a cosmetic carrier, a) at least one anionic surfactant (a), b) at least one amphoteric surfactant (b), c) at least one c2-c4 mono- and/or dialkanolamide (c) of at least one c8-c24 carboxylic acid, d) at least one polydimethylsiloxane (d), and e) at least one cationic polysaccharide (e), characterized in that i) the weight ratio of the anionic surfactant (a) to alkanolamide (c) is 15:1 to 7:1; and ii) the weight ratio of the amphoteric surfactant (b) to alkanolamide (c) is 12:1 to 5:1.. .
Henkel Ag & Co. Kgaa


02/18/16
20160044922 

Control of ectoparasites


Disclosed is a method of controlling ectoparasites that infest companion and livestock animals by applying to the animal an effective amount of 4-tert-butylphenethyl quinazolin-4-yl either or 4-chloro-5-ethyl-2-methyl-n-[(4-tert-butylphenyl)methyl]pyrazole-3-carboxamide or 5-chloro-n-[2-[4(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine.. .
Bayer Animal Health Gmbh


02/11/16
20160040088 

Natural oil derivative based thickener components used in grease compositions and processes for making such compositions


A grease composition is disclosed, having from 75 to 85 weight percent of a lubricating base oil, from 15 to 25 weight percent of a thickener component including one or more of (i) one or more natural oil derivatives comprising octadecanedioic acid dimethyl esters, (ii) one or more carboxylic acids and/or derivatives thereof, comprising 12-hydroxystearic acid, and (iii) one or more of a metal base compound comprising lithium hydroxide, and from 1 to 15 weight percent of one or more optional additives. Processes for making grease compositions are also disclosed..
Elevance Renewable Sciences, Inc.


02/11/16
20160039863 

Method for preparing substituted 3,7-dihydroxy steroids


The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-ethynyl-10r,13s-dimethyl 2,3,4,7,8r,9s, 10,11,12,13,14s,15,16,17-hexadecahydro-1h-cyclopenta[a]phenanthrene-3r,7r,17s-triol (also referred to as 17α-ethynyl-androst-5-ene-3β, 7β, 17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.. .
Neurmedix, Inc.


02/11/16
20160039832 

Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof


This invention relates to (1) process of making 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.. .
Astex Therapeutics, Ltd.


02/11/16
20160039742 

Extraction of tramadol from nauclea latifolia smith


A process for obtaining (±)-cis-2-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexanol includes the following steps: (a) extracting from roots of nauclea latifolia with an appropriate solvent, leading to a crude residue, and (b) purifying the crude residue to obtain a purified residue containing (±)-cis-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol.. .
Universite Joseph Fourier - Grenoble 1


02/11/16
20160039725 

Process for starting up a fluidized catalytic reaction apparatus used for producing lower olefins


Disclosed is a process for starting up fluidized reaction apparatus which are used for producing lower olefins from methanol or/and dimethyl ether. Said process includes after heating the catalyst bed of circulating fluidized catalytic reaction apparatus to above 200° c.
Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences


02/11/16
20160038887 

Polysulfone membrane having high selectivity


A spin dope composition produces a polymeric fiber useful in non-cryogenic gas separation. The composition includes polysulfone as the polymeric component, two solvents, in which the polymer is soluble, and a non-solvent, in which the polymer is insoluble.
Petroliam Nasional Berhad


02/04/16
20160033681 

Fabrication of lenses by droplet formation on a pre-heated surface


A lithography-free, mold-free, single-step method of fabricating high quality optical lenses by curing polydimethylsiloxane (pdms) droplets on a pre-heated smooth surface allows lenses with different focal lengths to be made by varying the droplet volume and surface temperature.. .
University Of Houston System


02/04/16
20160033522 

Methylcitrate analysis in dried blood spots


There is provided a method of measuring methylcitrate (mca) in a sample by derivatizing the mca, for example with 4-[2-(n,n-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (daabd-ae); measuring a level of the derivatized mca; and determining the level of mca from the measured level. The sample may be a dried blood spot (dbs), and the extraction and derivatization may be carried out simultaneously.
Children's Hospital Of Eastern Ontario


02/04/16
20160033389 

Stimulus responsive polymeric system


Herein, a polymer-based device capable of lifting many times its own mass was fabricated by drying a solution of the polycation poly (diallyldimethyl ammonium chloride) (pdadmac) on a surface coated with charged poly (n-isopropylacrylamide)-based microgels. Due to strong polymer-polymer and polymer-surface interactions, when the pdadmac solution dries on the microgel-modified surface, it bends.
The Governors Of The University Of Alberta


02/04/16
20160032115 

Solvent formulations


The present disclosure provides, in part, solvent compositions including an acetic acid alkyl (c—c) ester (e.g., methyl acetate (ma), ethyl acetate (ea), or tert-butyl acetate (tbac)) and a carbonate ester (e.g., dimethyl carbonate, or propylene carbonate), and optionally, a benzene-containing compound. The solvent compositions may be used to replace methyl ethyl ketone (mek)..
Tbf Environmental Technology Inc.


02/04/16
20160032042 

Process for producing flexible polyurethane foam using natural oil polyols


A composition and process useful to make flexible polyurethane foams and in particular flexible molded polyurethane foams is disclosed. The usage of dipolar aprotic liquids such as dmso, dmi, sulfolane, n-methyl-acetoacetamide, n, n-dimethylacetoacetamide as well as glycols containing hydroxyl numbers oh#≦1100 as cell opening aides for 2-cyanoacetamide or other similar molecules containing active methylene or methine groups to make a polyurethane foam is also disclosed.
Air Products And Chemicals, Inc.


02/04/16
20160031867 

An improved process for the preparation of aprepitant


The present invention provides a process for the preparation of 5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazole-3-one (aprepitant) comprising condensation of 2-(r)-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(s)-(4-fluorophenyl)morpholine hydrochloride salt with 2-(2-chloro-1-iminoethyl)hydrazinecarboxylic acid methyl ester to obtain the reaction mixture containing 2-[2-[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl]hydrazinecarboxylic acid methyl ester, which is in-situ cyclized in the presence of dimethylsulfoxide and a polar protic solvent at a low temperature to yield aprepitant having purity ≧99.5%.. .
Piramal Enterprises Limited


02/04/16
20160031822 

3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)


Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. .
Novartis Ag


02/04/16
20160031791 

Process for the production of acetic acid and dimethyl ether


A process for the production of acetic acid and dimethyl ether by contacting a mixture of methanol and methyl acetate with a zeolite catalyst wherein the zeolite has a 2-dimensional channel system comprising at least one channel having a 10-membered ring and having at least 5% of its cation exchange capacity occupied by one or more alkali metal cations.. .
Bp Chemicals Limited


02/04/16
20160030478 

Materials and methods to enhance hematopoietic stem cells engraftment procedures


This disclosure is directed to the methods of enhancing hematopoietic stem cells (hspc) and progenitor cell (hspc) engraftment procedure. Treatment in vivo of a hspc donor with compounds that reduce pge2 biosynthesis or pge2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as amd3100 and g-csf, increases the circulation of available hspcs.
Indiana University Research And Technology Corp.


02/04/16
20160030442 

Novel compounds


Wherein r1 is 2-indanyl, r2 is 1-methylpropyl, r3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, r4 represents methyl and r5 represents hydrogen or methyl or, r4 and r5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.. .

02/04/16
20160030395 

Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones


Disclosed are substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such 4 substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compound processes for the preparation thereof, and the use thereof for inhibiting bet family of bromodomains and for treating disorders mediated thereby, such as certain cancers.. .
Beigene, Ltd.


02/04/16
20160030366 

Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer


The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1r,4as,10ar)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (leelamine) and arachidonyl trifluoromethyl ketone (atk) in combination; methods for treatment of cancer including administration of leelamine and atk in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of leelamine and atk in a subject in need thereof..
The Penn State Research Foundation


02/04/16
20160030364 

Therapeutic compositions and uses thereof


This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2,4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided..
Manuka Health New Zealand Limited


01/28/16
20160024250 

Polymer compositions based on pxe


New polymer compositions based on poly(2,6-dimethyl-1,4-phenylene oxide) and other high-softening-temperature polymers are disclosed. These materials have a microphase domain structure that has an ionically-conductive phase and a phase with good mechanical strength and a high softening temperature.
Seeo, Inc


01/28/16
20160023976 

Process for the preparation of 3,7-dimethylnonan-1-ol


The present invention is related to a novel and improved process for the preparation of 3,7-dimethylnonan-1-ol.. .
Dsm Ip Assets B. V.


01/28/16
20160022860 

Minimizing biological lipid deposits on contact lenses


Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon a, lotrafilcon a, lotrafilcon b, and comfilcon a b with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt.
Bausch & Lomb Incorporated


01/28/16
20160022698 

Method for treating uterine fibroids


The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-n,n-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


01/28/16
20160022690 

Combination treatment


The present invention relates to the use of combinations comprising 8-[(1r)-1-(3,5-difluorophenylamino)ethyl]-n,n-dimethyl-2-morpholino-4-oxo-4h-chromene-6-carboxamide or a pharmaceutically acceptable salt thereof and a taxane in the treatment or prophylaxis of cancer; pharmaceutical compositions comprising compound [i] (or a pharmaceutically acceptable salt thereof) and a taxane; kits comprising compound [i] or a pharmaceutically acceptable salt thereof and a taxane, optionally with instructions for use; and methods of treatment comprising the simultaneous, sequential or separate administration of compound [i] or a pharmaceutically acceptable salt thereof and a taxane to warm-blooded animal, such as man.. .
Astrazeneca Ab


01/28/16
20160022676 

Topical medications for bruises and burns


Topical medications to treat the physical effects of bruises and burns. For bruises, the topical medication preferably includes therapeutically effective amounts of vasoconstrictor, such as phenylephrine hcl usp, an anti-inflammatory, such as arica, and compounding agents.
Meridian Research And Development, Inc.


01/28/16
20160022588 

Abuse-proofed oral dosage form


The present invention relates to an abuse-proofed oral dosage form with controlled release of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (a), at least one synthetic or natural polymer (c), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (b) and optionally a wax (d), component (c) or (d) in each case exhibiting a breaking strength of at least 500 n, preferably of at least 1000 n.. .
GrÜnenthal Gmbh


01/28/16
20160021873 

Stem cell preservation medium, stem cell preservation method, and stem cell preservation system


Provided are a stem cell preservation medium, stem cell preservation method and stem cell preservation system which can be used in a slow-freezing method that is used in place of vitrification, have a high cell survival rate and are convenient and highly efficient. The stem cell preservation medium comprises hydroxyethyl starch (hes), dimethyl sulfoxide (dmso), and ethylene glycol (eg).
Riken


01/21/16
20160016881 

Process for the carbonylation of dimethyl ether


A process for preparing methyl acetate by the carbonylation of dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein, in a first step the carbonylation is conducted with a carbon monoxide to hydrogen molar ratio of at least 1 and in a second and subsequent step, the carbonylation is conducted with a hydrogen to carbon monoxide molar ratio of greater than 1.. .
Bp Chemicals Limited


01/21/16
20160016878 

Process


A continuous process for the co-production of acetic acid and acetic anhydride by (a) contacting carbon monoxide with a liquid reaction composition comprising methyl acetate, dimethyl ether or a mixture thereof, a group viii metal catalyst, methyl iodide, acetic acid, acetic anhydride, water in a concentration of 0.1 wt % or less, (b) withdrawing liquid reaction composition from the reaction zone and introducing at least a portion of the withdrawn liquid reaction composition into a flash separation zone, and (c) removing from the flash separation zone a vapour fraction comprising acetic anhydride, acetic acid and methyl iodide and a liquid fraction comprising acetic anhydride, and group viii metal catalyst in which at least one of the liquid reaction composition and the withdrawn liquid reaction composition introduced into the flash separation zone comprises at least one metal salt selected from salts of group ia and group iia metals and the molar ratio of acetic acid to acetic anhydride in the vapour fraction removed from the flash separation zone is maintained at greater than or equal to 1, preferably greater than or equal to 1.2.. .
Bp Chemicals Limited


01/21/16
20160016341 

Method for making impact-absorptive material


A method for making an impact-absorptive material is introduced. The method involves mixing silicon dioxide (sio2) particles, polydimethylsiloxane (pdms), and an appropriate amount of an additive, allowing the mixture to settle until tiny bubbles in the mixture are evenly distributed, thereby forming a colloidal solution raw material, adding a crosslinking agent to the colloidal solution raw material to form a colloidal solution plastic material, filling a die with the colloidal solution plastic material, heating the colloidal solution plastic material in the die such that it takes shape and forms an effective impact absorbing material, quickly and at low costs, for use in physical education, medicine, transportation, and safety-enhancing equipment..
National Chung Shan Institute Of Science And Technology


01/21/16
20160016155 

Carbonylation catalyst and process


A catalyst and process for the production of methyl acetate by contacting dimethyl ether and carbon monoxide in the presence of a catalyst which is a zeolite of micropore volume of 0.01 ml/g or less.. .
Bp Chemicals Limited


01/21/16
20160015724 

Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid


The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.. .
Furiex Pharmaceuticals, Inc.


01/21/16
20160015700 

4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma


The present invention is directed to methods for the treatment of hodgkin's lymphoma comprising administering to a patient in need thereof, a therapeutically effective amount of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6 -(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide as mono-therapy or as combination or co-therapy with one or more chemotherapeutic agent or chemotherapy regimens.. .
Janssen Pharmaceutica Nv


01/14/16
20160011174 

Assay for determining the cell number in cultured cells


A method for determining the number of cells in an in vitro culture of cells is disclosed, the method comprising culturing cells in the presence of dimethyl sulphoxide (dmso) for a period of time sufficient for the cells to produce dimethyl sulphide (dms), measuring the dms produced by the cultured cells.. .
Keele University


01/14/16
20160011063 

Electronic skin, preparation method and use thereof


The invention provides a piezoresistive electronic skin, a preparation method and a use thereof. The piezoresistive electronic skin uses carbon nanotube film as the conductive layer and uses materials provided with micro-nano patterns, such as polydimethylsiloxane, polyethylene terephthalate, polyvinyl alcohol, polyvinyl formal, polyethylene, and so on, as the substrate, enabling the substrate has advantages of high flexibility and being pliable, and it needs low operating voltage and little power consumption, but has high sensitivity and short response time.
Suzhou Institute Of Nano-tech And Nano-bionics (sinano), Chinese Academy Of Science


01/14/16
20160009764 

Mu opioid receptor agonist analogs of the endomorphins


The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2′,6′-dimethyltyrosine (dmt) residue in place of the n-terminal tyrosine residue a position 1.
The Administrators Of The Tulane Educational Fund


01/14/16
20160009670 

Vortioxetine manufacturing process


A process for the manufacture of vortioxetine is provided in which a compound of formula i, formula i is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation.. .
H. Lundbeck A/s


01/14/16
20160009629 

Carbonylation process


A process for preparing methyl acetate by the carbonylation of dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein, in a first step the carbonylation is conducted with a carbon monoxide to hydrogen molar ratio of at least 1 and in a second and subsequent step, the carbonylation is conducted with a hydrogen to carbon monoxide molar ratio of greater than 1.. .
Bp Chemicals Limited


01/14/16
20160009006 

Sheet-shaped mold, production method therefor, and application therefor


Provided is a sheet-shaped mold possessing a high strength and having a low breakage rate in demolding even in a case where the mold is thin and has a large-area. The sheet-shaped mold is prepared by combining a cured silicone rubber containing a polyorganosiloxane and a fiber for reinforcing the cured silicone rubber.
Daicel Corporation


01/14/16
20160008368 

Combination


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a mtor inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or mtor is beneficial, e.g. Cancer..
Novartis Ag


01/14/16
20160008302 

Compounds and methods for treating aberrant adrenocortical cell disorders


Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (acc), cushing's syndrome and/or pituitary acth excess (cushing's disease). Such methods involve administration of an effective amount n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient..
Atterocor, Inc.


01/14/16
20160008246 

Sunscreen compositions and methods of their use


Described herein are compositions useful for protecting the skin from the sun. The compositions comprise cosmetic ingredients such as zinc oxide, titanium dioxide, butyloctyl salicylate, and a dermatologically acceptable vehicle.
Mary Kay Inc.


01/14/16
20160008244 

Sunscreen compositions and methods of their use


Described herein are topical skin compositions useful for protecting the skin from the sun. The topical skin compositions comprise cosmetic ingredients such as homosalate; octisalate; oxybenzone; octocrylene; avobenzone; c12-15 alkyl benzoate; dicaprylyl carbonate; glycerin; vp/eicosene copolymer; cetearyl alcohol; caprylyl methicone; ceteth-20 phosphate; silica; and ammonium acryloyldimethyltaurate/vp copolymer.
Mary Kay Inc.




Dimethyl topics: Physiologic, Hydrochloric Acid, Fresnel Zone, Aberration, Ophthalmic, Liquid Crystal, Imaging System, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Chloric Acid, Tartaric Acid, Fumaric Acid, Antagonist, Bradykinin, Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8876

4656

1 - 1 - 104